When breaking ground in a new industry, data is crucial. Over the last year, we have been collecting data and testimonies from clients who have come through our doors for treatment.
One of the scores we have had the most profound feedback on is the PHQ9. PHQ9 is one of the main measures of depression and is a scale that runs from 0 to 27 (27 being severe depression). The PHQ-9 can function as a screening tool, an aid in diagnosis, and a symptom-tracking tool that can help track a patient’s overall depression severity as well as the improvement of specific symptoms with treatment. The data in the chart shows the robust impact of our innovative and holistic Odyssey treatment.
The graph indicates the majority of Odyssey patients exhibited a significant drop in PHQ9 at approximately 3 months post-treatment. Given that most patients relapse following a ketamine treatment within 2-4 weeks, this data suggests that our Odyssey Ketamine-assisted Therapy framework can significantly extend symptom reductions for some patients. Effects were largest in patients with medium severity at baseline (PHQ9 = ~12-18).